ltra-high field MRI in DBS for epilepsy

Conditions: Epilepsy
Seizures
10039911

Registration Number: NL-OMON48769

Lead Sponsor: Medisch Universitair Ziekenhuis Maastricht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 15

Inclusion Criteria

All subjects must be mentally competent (wilsbekwaam) and able to understand the patient information form and decide for participation.
All subjects must be aged over 18 years old.
All subjects must meet all inclusion requirements of the standard Scannexus screening form
All subject must be included for DBS surgery at the MUMC+ for treatment of drug-resistant epilepsy

Exclusion Criteria

Neurological diseases other than epilepsy, such as brain tumours, stroke, severe neurotrauma*s, and neurodegenerative diseases.
Foreign ferromagnetic objects in the subject*s body or other contra indications for MRI. Prior to scanning, subjects will fill out a screening form. This form will be sent with the information letter to all subjects (Appendices 4 and 5). The screening form will be filled out again on the day of the scan, to ensure any contra indications are known to both the subject and the scanning technician.

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main radiological endpoint will be the location of the DBS electrode within<br /><br>the thalamic subnuclei and its structural and functional connectivity. De study<br /><br>parameters used are the DBS electrode contact coordinates (in y, x and z<br /><br>directions) and Euclidean distance of the implanted DBS electrode to the<br /><br>thalamic subnuclei defined by segmentation and by structural and functional<br /><br>MRI. The main clinical endpoint will be the reduction in seizure frequency<br /><br>after DBS. </p><br>

Secondary Outcome Measures